Tsukamoto Hirotake

ツカモトヒロタケ | Tsukamoto Hirotake

Affiliation and department：
Job title： Junior Associate Professor

Research field (1)： Immunology

Research keywords (5)： T細胞 , がん , 老化 , 免疫 , Immunology aging cancer

Research theme for competitive and other funds (9)：

2024 - 2027 がん免疫療法の有害事象と抗腫瘍免疫抑制に寄与するマクロファージサブセットの解明
2022 - 2025 development of therapeutic strategy for immune related adverse events by immune checkpoint inhivitor by focusing on B lymphocyte
2021 - 2024 免疫老化を基軸とした有害事象のマネジメント戦略とそれに基く新規がん免疫療法の開発
2018 - 2021 加齢随伴炎症を標的としたがん免疫療法の効果増強戦略の開発
2015 - 2018 Development of cancer immunotherapy using tumor-associated antigen-derived long peptides and liberation from immune suppression mediated trough IL-6 signaling

Show all

Papers (77)：

Kosuke Kanemitsu, Rin Yamada, Cheng Pan, Hirotake Tsukamoto, Hiromu Yano, Takuya Shiota, Yukio Fujiwara, Yuji Miyamoto, Yoshiki Mikami, Hideo Baba, et al. Age-Associated Reduction of Sinus Macrophages in Human Mesenteric Lymph Nodes. Journal of clinical and experimental hematopathology : JCEH. 2024
Yusuke Tomita, Shinya Sakata, Kosuke Imamura, Shinji Iyama, Takayuki Jodai, Koichi Saruwatari, Shohei Hamada, Kimitaka Akaike, Moriyasu Anai, Kazuaki Fukusima, et al. Association of Clostridium butyricum Therapy Using the Live Bacterial Product CBM588 with the Survival of Patients with Lung Cancer Receiving Chemoimmunotherapy Combinations. Cancers. 2023. 16. 1. 47-47
Yifang Shui, Xin Hu, Hiroshi Hirano, Hirotake Tsukamoto, Wen Zhi Guo, Kenichiro Hasumi, Fumihiro Ijima, Masayuki Fujino, Xiao Kang Li. Combined phospholipids adjuvant augments anti-tumor immune responses through activated tumor-associated dendritic cells. Neoplasia (United States). 2023. 39
Yuji Miura, Takanobu Motoshima, Toshiki Anami, Hiromu Yano, Remi Mito, Cheng Pan, Shinji Urakami, Keiichi Kinowaki, Hirotake Tsukamoto, Ryoma Kurahashi, et al. Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma. Microbiology and immunology. 2023
Yoshihiro Komohara, Daisuke Kurotaki, Hirotake Tsukamoto, Yuko Miyasato, Hiromu Yano, Cheng Pan, Yutaka Yamamoto, Yukio Fujiwara. Involvement of protumor macrophages in breast cancer progression and characterization of macrophage phenotypes. Cancer science. 2023

ｍore...

MISC (44)：

菰原義弘, 塚本博丈. 【がん免疫療法の個別化を支える新・腫瘍免疫学】第I部腫瘍免疫応答の基本とその制御メカニズム (第1章)腫瘍免疫応答の正負の調節機構がん免疫におけるマクロファージの役割病態形成における存在意義と標的細胞としての可能性. 実験医学. 2019. 37. 15. 2443-2451
塚本博丈, 押海裕之. 【がん免疫と免疫療法】IL-6とPD-1/PD-L1シグナルの併用阻害による免疫抑制効果の相互制御の遮断. 臨床免疫・アレルギー科. 2019. 72. 2. 165-173
栗山春香, 福島聡, 木村俊寛, 石橋卓行, 門久美菜, 久保陽介, 中原智史, 宮下梓, 猪爪隆史, 塚本博丈, et al. 悪性黒色腫に対する4-1BBリガンド導入iPS細胞由来ミエロイドラインを用いた免疫療法. 日本がん免疫学会総会プログラム・抄録集. 2019. 23回. 110-110
Yasuharu Nishimura, Koji Fujieda, Azusa Miyashita, Satoshi Fukushima, Tokunori Ikeda, Yosuke Kubo, Satoru Senju, Hironobu Ihn, Hiroyuki Oshiumi, Hirotake Tsukamoto. Combination of anti-IL-6 and anti-PD-L1 antibodies synergistically reinvigorates cancer immunity by activating both CTL and Th1 cells in mice. CANCER RESEARCH. 2019. 79. 13
Hirotake Tsukamoto, Koji Fujieda, Azusa Miyashita, Satoshi Fukushima, Tokunori Ikeda, Yosuke Kubo, Satoru Senju, Hironobu Ihn, Yasuharu Nishimura, Hiroyuki Oshiumi. Combined blockade of IL-6 and PD-1/PD-L1 signals breaks mutual regulation of their immunosuppressive effects. CANCER SCIENCE. 2018. 109. 624-624

ｍore...

Books (13)：

免疫チェックポイント分子によるがん免疫制御、耐性、副反応
科学評論社 2023
Mechanisms underlying immune-related adverse events associated with anti-PD-(L)1 therapy
2023
Precision Medicine "Development of combined cancer immunotherapy based on age-associated immune dysfunction"
2020
The role of macrophages in anti-tumor immune response
Yodosha 2019
「IL-6とPD-1/PD-L1シグナルの併用阻害による免疫抑制効果の相互制御の遮断」臨床免疫・アレルギー科
科学評論社 2019

ｍore...

Lectures and oral presentations (14)：

Exosomal miR192 regulates inflammatory response induced by Influenza whole vaccine
(2019)
Targeting of age-associated increased in IL-6 improves the responsiveness to cancer immunotherapies in old age
(2019)
Combined blockade of IL-6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment
(2018)
Combined blockade of IL-6 and PD-1/PD-L1 signals breaks mutual regulation of their immunosuppressive effects
(2018)
Combined blockade of IL-6 and PD-1/PD-L1 signals breaks mutual regulation of their immunosuppressive effects in tumor
(2017)

ｍore...

Works (4)：

老齢個体のT細胞増殖不全と、それによるがん免疫療法効果低下におけるHippo経路の関与
2015 - 2017
CD4+T細胞を介した抗腫瘍免疫応答に対する可溶性IL-6受容体の影響の解析
2013 - 2014
担癌固体でのCD4+T細胞機能不全の発生機序におけるミエロイド系抑制性細胞(MDSC)由来のIL-6の影響についての検討
2012 - 2013
担癌個体におけるミエロイド系抑制性細胞によるT細胞機能不全の発生機序の解明
2010 - 2011

Education (3)：

2002 - 2006 Kumamoto University
2000 - 2002 Kumamoto University
1996 - 2000 Tottori University

Professional career (1)：

Ph.D (Kumamoto University)

Work history (3)：

2016/04 - 2021/03 Graduate School of Medical Sciences, Kumamoto University Department of Immunology
2010 - Kumamoto University Faculty of Life Sciences
2010 - Assistant Professor,Faculty of Life Sciences(Basic medicine group),Kumamoto University

Committee career (1)：

2015 - 現在日本がん免疫学会評議員

Awards (4)：

2018/12 - Japanese Society of Immunology Best Presentation Award
2016/11 - Research Achievement Award
2013 - Young Investigator Award
2013 - Tadamitsu Kishimoto International Travel Award

Association Membership(s) (4)：

アメリカ免疫学会 , 日本がん免疫学会 , 免疫学会 , American Association of Immunologists

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page